Adjuvant atezolizumab combined with mFOLFOX6 halved the risk of disease recurrence or death in patients with resected stage III mismatch repair–deficient colon cancer in the phase 3 ATOMIC trial.
Real-world data from Fall Clinical 2026 reveal widespread treatment dissatisfaction, anxiety, and steroid hesitancy among ...
Risk for ischemic stroke, myocardial infarction were increased with prolonged use with doses >1 mg/day for more than one year ...
Many approved prescriptions are never filled, with fill rates dropping sharply when out-of-pocket costs exceed $175.
Second study shows that individuals exposed to GLP-1 RAs have significantly higher prevalence rates of hair and scalp involvement.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results